Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Mesoblast Limited (MESO) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs Mesoblast Limited — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $48.02, while Mesoblast Limited trades at $17.88 (market cap $2.12B). The key difference: Mesoblast Limited is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.

BNDXMESO
52-Week High
$49.91$20.96
52-Week Low
$47.57$10.96
Market Cap
$2.12B
Sector
Technology
Enterprise Value
$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.89, down 0.4% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators but faces pressure from rising bond yields and Fed uncertainty. Recent news highlights strong bond ETF inflows as investors seek yield amid market volatility, though inflation concerns persist.

Outlook remains cautious due to potential Fed rate hikes and macroeconomic headwinds. The fund offers steady income through dividends but faces valuation pressure from rising rates. Key risks include interest rate sensitivity and global economic shifts impacting international bond performance.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO